Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome

N/ACompletedNCT01952392

AstraZeneca4,992 enrolled

Overview

Prevention of cardiovascular events by antiplatelet agents after acute coronary syndrome

AReMIS (Antiplatelet and Recurrent Myocardial Infarction Study) To compare the relative risk of new myocardial infarction (recurrent myocardial infarction or 'rMI') in patients with a history of acute coronary syndrome ('ACS': unstable angina or myocardial infarction), using ticagrelor, clopidogrel or prasugrel (if applicable) or none of these treatments, where aspirin is considered a covariate.

Study Type

OBSERVATIONAL

Enrollment

4,992

Conditions

Acute Coronary Syndrome

Eligibility

Sex: ALLMin age: 18 YearsMax age: 130 Years

Medical Language ↔ Plain English

Inclusion Criteria: Patients aged 18 years or more, both genders, with an acute coronary syndrome (ACS), agreed to participate and able to respond to an interview in French and/or providing the details of an alternative replier (proxy) if necessary. No Exclusion Criteria.

Locations (1)

Research Site

Paris, France

Outcomes

Primary Outcomes

Medical information

History of coagulation and vascular disorders History of cerebrovascular accidents Cardiovascular risk factors

Time frame: At baseline visit

Drug exposure

Current exposure: within 24 hours (before date of recurrent MI). Exposure to clopidogrel, ticagrelor, prasugrel, aspirin, other antiplatelet drugs.

Time frame: Current

Drug exposure

Recent exposure: in the week (7 days) preceding the recurrent MI. Exposure to clopidogrel, ticagrelor, prasugrel, aspirin, other antiplatelet drugs.

Time frame: Recent

Drug exposure

Past exposure: more than a week (7 days) before the recurrent MI and until the ACS index. Exposure to clopidogrel, ticagrelor, prasugrel, aspirin, other antiplatelet drugs.

Time frame: Past

Secondary Outcomes

Other medical events of interest

rMI, stroke, bleeding, death

Time frame: During follow-up (up to 12 months)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.